Domov › Akútna myeloidná leukémia › Arkansas
Klinické štúdie Akútna myeloidná leukémia v štáte Arkansas
13 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v štáte Arkansas.
Mestá v štáte Arkansas
Oficiálny text štúdie (anglicky)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Fort Smith, Fort Smith
- CARTI Cancer Center, Little Rock
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Arkansas at Little Rock, Little Rock
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Arkansas for Medical Sciences, Little Rock
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Arkansas Children's Hospital, Little Rock
Prebieha náborFáza 3
6 Months – 21 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Arkansas Children's Hospital, Little Rock
Prebieha náborFáza 3
Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Arkansas Children's Hospital, Little Rock
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Arkansas Children's Hospital, Little Rock
Prebieha náborFáza 3
29 Days – 21 Years · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Arkansas Children's Hospital, Little Rock
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Arkansas Children's Hospital, Little Rock
Prebieha náborFáza 1
Do veku 21 · Všetky pohlavia · Aktualizované 22. 4. 2026 · NCT05101551Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.